Results 171 to 180 of about 36,253 (296)

MYO6 and Heart: A Novel Variant in a Deaf Infant With Supraventricular Tachycardia

Molecular Genetics &Genomic Medicine, Volume 14, Issue 6, June 2026.
A novel homozygous frameshift variant in the MYO6 gene (c.2496_2497delAC; p.H833Qfs*5) was identified in a neonate presenting with bilateral congenital sensorineural hearing loss, paroxysmal supraventricular tachycardia (SVT), and prolonged QT interval.
Samira Kalayinia, Tannaz Masoumi, Amirreza Taherkhani, Nejat Mahdieh, Mohammadrafie Khorgami, Majid Maleki   +5 more
wiley   +1 more source

Assessing modifiable risk factors for atrial fibrillation/flutter in the young: a hybrid local-global study. [PDF]

Front Endocrinol (Lausanne)
Liu Y, Liu L, Zhou Q, Liu Y, Song J.
europepmc   +1 more source

A Spatio‐Temporal Diffusion Model for Cardiac Real‐Time Imaging

Magnetic Resonance in Medicine, Volume 95, Issue 6, Page 3574-3583, June 2026.
ABSTRACT Purpose Real‐time imaging of cardiac function is favorable due to shorter scan times and becomes necessary when arrhythmia or inability to hold breath leads to insufficient quality of electrocardiogram (ECG)‐gated Cartesian cine. However, comparable spatio‐temporal resolution can only be achieved in undersampled settings, which in turn demand ...
Oliver Schad, Julius Frederik Heidenreich, Nils Petri, Viktor Hartung, Alena Kollmann, Thorsten Alexander Bley, Peter Nordbeck, Bernhard Petritsch, Tobias Wech   +8 more
wiley   +1 more source

Sex‐based differences in outcomes between male and female patients with bicuspid aortic stenosis following transcatheter aortic valve replacement: A meta‐analysis

Precision Medical Sciences, Volume 15, Issue 2, Page 70-79, June 2026.
Central illustration: Sex‐based differences in outcomes between male and female patients with bicuspid aortic stenosis following transcatheter aortic valve replacement. Abstract Bicuspid aortic valve (BAV) is a common congenital anomaly leading to early aortic stenosis.
Muhammad Huzaifa Ahmed Khan, Muneeb Khawar, Asad Ullah Farooq, Azooba Khalid, Syed Muhammad Ahsan, M. Hamza Naseer Awan, Muhammad Soban Nisar, Asim Elahi, Muhammad Aqib Faizan, Iqra Shahid, Abdullah Munir Ahmed, Faseeh Haider, Rejina Chhetri   +12 more
wiley   +1 more source

Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. Omega‐3 fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been extensively studied for potential cardioprotective effects, yet their impact on cardiovascular outcomes ...
Sepideh Karkon Shayan, Rosull Saadoon Abbood, Sarah F. Al‐Taie, Paria Ganji Nataj, Maksudova Malika Khamdamjonovna, Siamak Aminnezhad, Yasaman Ghodsi Boushehri, Jabbarov Jamoliddin Sindorovich, Ali Sinehsepehr, Farshad Zare, Seyed Abbas Pakmehr, Elham Abdollahi, Milad Vahedinezhad   +12 more
wiley   +1 more source

Benzofuran‐Based Uricosuric Agents: History, Roles, and Challenges

ChemistrySelect, Volume 11, Issue 24, 25 June 2026.
Benzofuran‐based uricosuric agents represent a privileged medicinal chemistry scaffold for gout therapy. Structural optimization of benzbromarone‐related derivatives has improved hURAT1 inhibitory potency, metabolic stability, and urate‐lowering efficacy, while reducing hepatotoxic liability.
Raed M. Al‐Zoubi, Basma Hanbali, Mai Elaarag, Zainab Fares, Enas A. Al‐Hurani, Sally R. Al‐Zoubi, Mohanad Shkoor, Abdelali Agouni   +7 more
wiley   +1 more source

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper, Grace Lenaghan, Aaron Stockwell, Matthew Schmidt, Katharine Ingram, Andrew C. Stafford   +5 more
wiley   +1 more source

Time of day of cardiac surgery and postoperative outcomes in the UK: a secondary analysis of linked national datasets

Anaesthesia, Volume 81, Issue 6, Page 775-782, June 2026.
Summary Introduction Uncertainty remains regarding whether the time of day that cardiac surgery is performed affects postoperative outcomes or if the observed variation can be explained by patient or surgical factors. Methods A secondary analysis of prospectively collected data was conducted to examine the association between time of cardiac surgery ...
Gareth Kitchen, Karen Thomas, Tim Felton, Hannah Durrington, John Blaikley, Stuart W. Grant, David Harrison, Peter McGuigan, Kathryn Rowan, Anthony Wilson, Danny McAuley, Paul Dark   +11 more
wiley   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 12, Page 1673-1684, June 2026.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5163-5173, June 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan, Jason C. Hsu, Christine Y. Lu   +2 more
wiley   +1 more source